
Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19), hepatitis B Virus (HBV) and human metapneumovirus (hMPV).
Volume:
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Recent Press Releases
September 17, 2023
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
September 7, 2023
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
Upcoming Events
Sep 26, 2023 at 8:45 AM EDT
2023 Cantor Global Healthcare Conference
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR